
    
      Primary objective: The objective of this trial is to demonstrate the efficacy of alirocumab
      150 mg every 2 weeks over 12 weeks on cholesterol levels.

      Secondary objective: To assess the safety of treating chronic dialysis patients with
      alirocumab 150 mg subcutaneously every 2 weeks for 12 weeks.

      Secondary objective: To demonstrate the efficacy of alirocumab 150 mg every 2 weeks over 12
      weeks on biomarkers.

      Exploratory objective: To assess alirocumab drug levels in subjects maintained on
      hemodialysis and peritoneal dialysis.

      Methodology: Open-label, nonrandomized study

      Number of patients Ten patients maintained on stable hemodialysis for a minimum of 3 months
      and ten patients maintained on stable peritoneal dialysis for a minimum of 3 months

      Test product: alirocumab 150 mg

      Mode of administration: administered subcutaneously

      Dosing interval: every 2 weeks

      Duration of treatment: 12 weeks

      Primary endpoint: Levels of LDL-cholesterol at 12 weeks

      Secondary endpoints: Levels of total cholesterol, triglycerides, apoprotein B, Cystatin-C,
      fibrinogen, hsCRP, IL-6, NGAL, NT-proBNP, soluble CD40 ligand, troponin T, VCAM

      Safety criteria: Adverse events, Incidence and intensity of AE, including serious AE (SAE),
      Withdrawal from study medication due to AE, Clinical relevant new findings or worsening of
      existing conditions physical examination, Clinically relevant changes in laboratory
      measurements from baseline
    
  